Adenocarcinoma Of Pancreas — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for adenocarcinoma of pancreas. 41 active patents protecting 3 drugs from 3+ originators. First major cliff: 2030. Daily refresh.

3
Approved drugs
41
Active US patents
52/100
Avg vulnerability
—
Annual revenue covered

Originators in Adenocarcinoma Of Pancreas

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Accord Hlthcare 15 patents Pfizer 14 patents Kyowa Kirin Co., Ltd. 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating adenocarcinoma of pancreas. Each bar = one year. Y-axis scaled to peak year (18 patents).

2
26
1
27
2
28
2
29
2
30
7
31
1
32
18
33
2
34
4
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Gemzar
Gemcitabine Hydrochloride
 Accord Hlthcare 15 48 — 2030-06-28
Camptosar
Irinotecan Hydrochloride
 Pfizer 14 55 — 2027-01-06
Mitozytrex
MITOMYCIN
 Kyowa Kirin Co., Ltd. 12 52 — 2026-07-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12364691 Camptosar method of use 75 2033-06-12
11344552 Camptosar method of use 75 2036-08-19
11369597 Camptosar method of use 70 2033-06-12
9040074 Mitozytrex method of use 64 2031-01-20
12440568 Mitozytrex method of use 64 2031-01-20
12268745 Mitozytrex method of use 64 2031-01-20
9950069 Mitozytrex method of use 64 2031-01-20
10039832 Mitozytrex method of use 64 2031-01-20
10980795 Camptosar method of use 62 2033-06-12
9492442 Camptosar method of use 62 2033-06-12

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8147867 Camptosar composition of matter 17 2028-08-29
8329213 Camptosar composition of matter 22 2027-01-06
9950069 Mitozytrex formulation 31 2031-01-20
9040074 Mitozytrex formulation 31 2031-01-20
10456360 Camptosar formulation 42 2036-10-15
10993914 Camptosar formulation 42 2036-10-15
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01
9241948 Gemzar formulation 42 2033-07-01

Related